Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Wed, 24 Jun 2026 08:00:00 -0400

VANCOUVER, BC, June 24, 2026 /PRNewswire/ -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company advancing next-generation solutions for women's health, today announced that granted a new patent No. 12654025B2 — a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact.

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Wed, 24 Jun 2026 08:00:00 -0400

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Wed, 24 Jun 2026 08:00:00 -0400

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Wed, 24 Jun 2026 08:00:00 -0400

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Wed, 24 Jun 2026 08:00:00 -0400

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Wed, 24 Jun 2026 08:00:00 -0400

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Wed, 24 Jun 2026 08:00:00 -0400

Zero Candida announced officially been granted Patent No. 12654025B2 -- a meaningful milestone that reflects our commitment to innovation, technology, and long-term impact

Wed, 24 Jun 2026 08:00:00 -0400

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Tue, 17 Feb 2026 08:00:00 -0400

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women

VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company advancing next-generation solutions for women's health, today announced that it is scaling manufacturing to 250 clinical-grade prototypes of its ZC-001 therapeutic device under ISO 13485-certified quality standards.

This production milestone is a

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Tue, 17 Feb 2026 08:00:00 -0400

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women

This production milestone is a

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Tue, 17 Feb 2026 08:00:00 -0400

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women

This production milestone is a

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Tue, 17 Feb 2026 08:00:00 -0400

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women

This production milestone is a

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Tue, 17 Feb 2026 08:00:00 -0400

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women

This production milestone is a

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Tue, 17 Feb 2026 08:00:00 -0400

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women

This production milestone is a

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Tue, 17 Feb 2026 08:00:00 -0400

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women

This production milestone is a

Zero Candida Scales Production to 250 ISO 13485 Clinical-Grade Prototypes of ZC-001 Therapeutic Device

Tue, 17 Feb 2026 08:00:00 -0400

Supports GLP preclinical testing and planned Q4 2026 clinical study of at least 100 women

This production milestone is a

Zero Candida Achieves Design Freeze and Begins Prototype Production of ZC-001 Therapeutic Device